Methyl-CpG binding domain protein 2 (Mbd2) drives breast cancer progression through the modulation of epithelial-to-mesenchymal transition

Experimental & Molecular Medicine, Published online: 01 April 2024; doi:10.1038/s12276-024-01205-2DNA methylation, a process that regulates how genes work, is often disturbed in cancer. This research looked at the role of Methyl-CpG-Binding Domain Protein 2 (MBD2), a protein that interprets these methylation signals, in breast cancer. It was found that MBD2 is overly active in several kinds of cancer, including breast cancer. In an experiment with mice, it was found that removing MBD2 slowed down the formation of tumors and reduced the spread of cancer. MBD2 was found to control several genes involved in how cancer progresses and how the immune system responds. The research suggests that focusing on MBD2 could be a possible treatment approach for breast cancer.This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
Source: Experimental and Molecular Medicine - Category: Molecular Biology Authors: Source Type: research